Kiora Pharmaceuticals, Inc. (KPRX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol KPRX
- Company Kiora Pharmaceuticals, Inc.
- Price $1.63
- Changes Percentage 4.49
- Change 0.07
- Day Low $1.61
- Day High $1.85
- Year High $2.95
- Year Low $1.77
- Market Cap $11,833,280
- Price Avg 50 EMA (D) $2.59
- Price Avg 200 EMA (D) $2.37
- Exchange NASDAQ
- Volume 19,375
- Average Volume 17,874
- Open $1.79
- Previous Close $1.56
- EPS -2.51
- PE -1.06
- Earnings Announcement 2026-11-06 12:00:00
- Shares Outstanding $4,431,940
Company brief: KIORA PHARMACEUTICALS, INC. (KPRX )
- Healthcare
- Biotechnology
- Dr. Brian M. Strem Ph.D.
- https://www.kiorapharma.com
- US
- N/A
- 02-13-2015
- US49721T3095
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.